0001104659-21-127874.txt : 20211020 0001104659-21-127874.hdr.sgml : 20211020 20211020074737 ACCESSION NUMBER: 0001104659-21-127874 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20211020 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211020 DATE AS OF CHANGE: 20211020 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 211332744 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 8-K 1 tm2130546d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

October 20, 2021

Date of Report (Date of earliest event reported)

ABBOTT LABORATORIES

(Exact name of registrant as specified in charter)

Illinois		1-2189		36-0698440
(State or other Jurisdiction		(Commission File Number)		(IRS Employer
of Incorporation)				Identification No.)

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (224) 667-6100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12(b) of the Act:

Title of Each Class

Trading
Symbol(s)

Name of Each Exchange

on Which Registered

Common Shares, Without Par Value

ABT

New York Stock Exchange
Chicago Stock Exchange, Inc.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02

Results of Operations and Financial Condition

On October 20, 2021, Abbott Laboratories announced its results of operations for the third quarter 2021.

Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings from continuing operations excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, restructuring actions, cost reduction initiatives, certain litigation, the acquisition of an R&D asset, the impairment of certain assets, the gain on the disposition of an equity method investment, tax benefits associated with specified items, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance. Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.

Item 9.01

Financial Statements and Exhibits

Exhibit No.		Exhibit

99.1		Press Release dated October 20, 2021 (furnished pursuant to Item 2.02).

104		Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ABBOTT LABORATORIES


Date: October 20, 2021	By:	/s/ Robert E. Funck, Jr.
		Robert E. Funck, Jr.
		Executive Vice President, Finance and Chief Financial Officer

EX-99.1 2 tm2130546d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

News Release

Abbott Reports Third-Quarter 2021 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance

-

Third-quarter sales growth of 23.4 percent; organic sales growth of 22.4 percent

-

GAAP diluted EPS from continuing operations growth of 69.6 percent; adjusted diluted EPS growth of 42.9 percent

-

Global COVID-19 testing-related sales were $1.9 billion in the third quarter

-

Excluding COVID-19 testing-related sales, third-quarter sales grew 11.7 percent on both a reported and organic basis compared to sales in 2019

-

Continues to strengthen portfolio with several new product approvals

ABBOTT PARK, Ill., Oct. 20, 2021 — Abbott today announced financial results for the third quarter ended Sept. 30, 2021.

·

Third-quarter sales of $10.9 billion increased 23.4 percent on a reported basis and 22.4 percent on an organic basis, which excludes the impact of foreign exchange.

·

Third-quarter GAAP diluted EPS was $1.17 and adjusted diluted EPS, which excludes specified items, was $1.40, reflecting 42.9 percent growth versus the prior year.¹

·

Abbott projects full-year 2021 diluted EPS from continuing operations on a GAAP basis of $3.55 to $3.65 and full-year adjusted diluted EPS from continuing operations of $5.00 to $5.10, reflecting growth of 38.4 percent at the mid-point versus prior year.²

·

In August, Abbott announced U.S. FDA approval of its Amplatzer^®Amulet^®device, which offers immediate closure of the left atrial appendage – an area in the heart where blood clots can form.

·

In August, Abbott announced results of the company's GUIDE-HF clinical trial, which showed Abbott's CardioMEMS^® remote monitoring system can improve care for more patients living with heart failure. Abbott filed a Premarket Approval (PMA) supplement with the FDA for consideration of an expanded indication for CardioMEMS.

·

In September, Abbott announced U.S. FDA approval of its Portico^®with FlexNav^®transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery.

·

During the third quarter, Abbott acquired Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive thrombectomy system designed to remove peripheral blood clots.

"We achieved another quarter of strong growth overall and across all four of our major business areas," said Robert B. Ford, president and chief executive officer, Abbott. "We're particularly pleased with the continued advancements of our new product pipeline, including several recent launches in large, high-growth markets."

—more—

THIRD-Quarter Business Overview

Note: Management believes that measuring sales growth rates on an organic basis is an appropriate way for investors to best understand the underlying performance of the business. Organic sales growth excludes the impact of foreign exchange.

Following are sales by business segment and commentary for the third quarter 2021:

Total Company

($ in millions)

														% Change vs. 3Q20
		Sales 3Q21												Reported												Organic
		U.S.				Int'l				Total				U.S.				Int'l				Total				U.S.				Int'l				Total
Total *			4,368				6,560				10,928				31.2				18.7				23.4				31.2				17.0				22.4
Nutrition			919				1,189				2,108				12.3				7.6				9.6				12.3				6.5				8.9
Diagnostics			1,947				1,965				3,912				71.8				30.5				48.2				71.8				28.0				46.8
Established Pharmaceuticals			--				1,265				1,265				n/a				15.1				15.1				n/a				15.3				15.3
Medical Devices			1,496				2,136				3,632				9.7				18.2				14.6				9.7				15.7				13.1

* Total Q3 2021 Abbott sales from continuing operations include Other Sales of approximately $11 million.

														% Change vs. 9M20
		Sales 9M21												Reported												Organic
		U.S.				Int'l				Total				U.S.				Int'l				Total				U.S.				Int'l				Total
Total *			11,787				19,820				31,607				33.6				31.4				32.2				33.6				27.3				29.6
Nutrition			2,628				3,624				6,252				7.8				10.7				9.5				7.8				8.7				8.3
Diagnostics			4,743				6,430				11,173				69.8				75.3				73.0				69.8				68.7				69.2
Established Pharmaceuticals			--				3,515				3,515				n/a				11.4				11.4				n/a				12.0				12.0
Medical Devices			4,385				6,233				10,618				23.1				25.5				24.5				23.1				19.0				20.7

* Total 9M 2021 Abbott sales from continuing operations include Other Sales of approximately $49 million.

n/a = Not Applicable.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

Third-quarter 2021 worldwide sales of $10.9 billion increased 23.4 percent on a reported basis and 22.4 percent on an organic basis.

Compared to pre-pandemic sales in 2019, worldwide sales, excluding COVID-19 testing-related sales³, increased 11.7 percent on both a reported and organic basis in the third quarter.

2

Nutrition

($ in millions)

																% Change vs. 3Q20
				Sales 3Q21												Reported												Organic
				U.S.				Int'l				Total				U.S.				Int'l				Total				U.S.				Int'l				Total
	Total				919				1,189				2,108				12.3				7.6				9.6				12.3				6.5				8.9
	Pediatric				586				514				1,100				20.2				(0.8	)			9.4				20.2				(2.2	)			8.6
	Adult				333				675				1,008				0.6				15.0				9.8				0.6				14.1				9.3

																% Change vs. 9M20
				Sales 9M21												Reported												Organic
				U.S.				Int'l				Total				U.S.				Int'l				Total				U.S.				Int'l				Total
	Total				2,628				3,624				6,252				7.8				10.7				9.5				7.8				8.7				8.3
	Pediatric				1,622				1,637				3,259				8.9				0.5				4.5				8.9				(1.7	)			3.4
	Adult				1,006				1,987				2,993				6.0				20.9				15.5				6.0				18.9				14.2

Worldwide Nutrition sales increased 9.6 percent on a reported basis and 8.9 percent on an organic basis in the third quarter. Strong performance of Ensure^®, Abbott's market-leading complete and balanced nutrition brand, and Glucerna^®, Abbott's market-leading diabetes nutrition brand, led to global Adult Nutrition sales growth of 9.8 percent on a reported basis and 9.3 percent on an organic basis.

Worldwide Pediatric Nutrition sales increased 9.4 percent on a reported basis and 8.6 percent on an organic basis. Strong performance of Abbott's market-leading oral hydration brand, Pedialyte^®, and continued share growth in infant nutrition led to U.S. Pediatric Nutrition growth of 20.2 percent.

3

Diagnostics

($ in millions)

														% Change vs. 3Q20
		Sales 3Q21												Reported												Organic
		U.S.				Int'l				Total				U.S.				Int'l				Total				U.S.				Int'l				Total
Total			1,947				1,965				3,912				71.8				30.5				48.2				71.8				28.0				46.8
Core Laboratory			291				1,001				1,292				2.4				12.2				9.9				2.4				9.9				8.1
Molecular			162				183				345				(26.2	)			(23.1	)			(24.6	)			(26.2	)			(25.0	)			(25.6	)
Point of Care			100				35				135				3.9				1.5				3.3				3.9				(0.1	)			2.8
Rapid Diagnostics			1,394				746				2,140				161.4				118.5				144.7				161.4				115.0				143.3

														% Change vs. 9M20
		Sales 9M21												Reported												Organic
		U.S.				Int'l				Total				U.S.				Int'l				Total				U.S.				Int'l				Total
Total			4,743				6,430				11,173				69.8				75.3				73.0				69.8				68.7				69.2
Core Laboratory			845				2,935				3,780				0.6				26.9				19.9				0.6				22.1				16.4
Molecular			431				651				1,082				0.5				23.5				13.2				0.5				17.6				9.9
Point of Care			289				112				401				4.0				2.5				3.6				4.0				(1.0	)			2.6
Rapid Diagnostics			3,178				2,732				5,910				154.9				280.1				200.7				154.9				266.6				195.8

Worldwide Diagnostics sales increased 48.2 percent on a reported basis in the third quarter and increased 46.8 percent on an organic basis. Global COVID-19 testing-related sales were $1.9 billion in the third quarter, led by combined sales of $1.6 billion from Abbott's BinaxNOW^®, Panbio^® and ID NOW^® rapid testing platforms. Excluding COVID-19 testing-related sales, worldwide diagnostics sales increased 14.1 percent on a reported basis in the third quarter and 12.5 percent on an organic basis.⁴

Compared to the pre-pandemic 2019 baseline, sales in Core Laboratory and Molecular Diagnostics, excluding COVID-19 testing-related sales, grew 5.8 percent and 14.9 percent, respectively, on a reported basis in the third quarter and grew 4.9 percent and 13.6 percent, respectively, on an organic basis.⁵

4

Established Pharmaceuticals

($ in millions)

														% Change vs. 3Q20
		Sales 3Q21												Reported										Organic
		U.S.				Int'l				Total				U.S.		Int'l				Total				U.S.				Int'l				Total
Total			--				1,265				1,265			n/a			15.1				15.1				n/a				15.3				15.3
Key Emerging Markets			--				936				936			n/a			17.1				17.1				n/a				17.9				17.9
Other			--				329				329			n/a			9.7				9.7				n/a				8.5				8.5

														% Change vs. 9M20
		Sales 9M21												Reported										Organic
		U.S.				Int'l				Total				U.S.		Int'l				Total				U.S.				Int'l				Total
Total			--				3,515				3,515			n/a			11.4				11.4				n/a				12.0				12.0
Key Emerging Markets			--				2,672				2,672			n/a			12.4				12.4				n/a				14.2				14.2
Other			--				843				843			n/a			8.1				8.1				n/a				5.4				5.4

Established Pharmaceuticals sales increased 15.1 percent on a reported basis in the third quarter and increased 15.3 percent on an organic basis.

Key Emerging Markets include India, Brazil, Russia and China along with several additional emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 17.1 percent on a reported basis in the quarter and increased 17.9 percent on an organic basis. Organic sales growth was led by strong growth across several geographies, including China, Russia and India.

Other sales increased 9.7 percent on a reported basis in the quarter and increased 8.5 percent on an organic basis.

5

Medical Devices

($ in millions)

														% Change vs. 3Q20
		Sales 3Q21												Reported												Organic
		U.S.				Int'l				Total				U.S.				Int'l				Total				U.S.				Int'l				Total
Total			1,496				2,136				3,632				9.7				18.2				14.6				9.7				15.7				13.1
Rhythm Management			266				305				571				9.6				15.3				12.6				9.6				12.7				11.2
Electrophysiology			192				293				485				(0.1	)			17.6				9.9				(0.1	)			15.9				8.9
Heart Failure			170				59				229				17.6				28.0				20.1				17.6				25.4				19.5
Vascular			219				425				644				(4.3	)			6.3				2.5				(4.3	)			3.9				0.9
Structural Heart			177				215				392				11.2				10.9				11.0				11.2				9.2				10.1
Neuromodulation			149				41				190				(12.5	)			13.8				(7.9	)			(12.5	)			11.5				(8.3	)
Diabetes Care			323				798				1,121				43.1				29.4				33.0				43.1				26.0				30.6

														% Change vs. 9M20
		Sales 9M21												Reported												Organic
		U.S.				Int'l				Total				U.S.				Int'l				Total				U.S.				Int'l				Total
Total			4,385				6,233				10,618				23.1				25.5				24.5				23.1				19.0				20.7
Rhythm Management			776				881				1,657				18.5				21.2				19.9				18.5				14.9				16.6
Electrophysiology			580				823				1,403				21.8				26.2				24.4				21.8				20.9				21.3
Heart Failure			483				167				650				17.5				18.7				17.8				17.5				12.5				16.2
Vascular			684				1,292				1,976				8.9				16.7				13.9				8.9				11.2				10.4
Structural Heart			537				654				1,191				39.0				28.8				33.2				39.0				22.3				29.5
Neuromodulation			460				124				584				17.4				28.3				19.6				17.4				20.8				18.1
Diabetes Care			865				2,292				3,157				41.0				32.0				34.3				41.0				24.3				28.7

Worldwide Medical Devices sales increased 14.6 percent on a reported basis in the third quarter and increased 13.1 percent on an organic basis. Strong growth in the quarter was driven by continued recovery from the COVID-19 pandemic and strong growth in Diabetes Care.

Compared to pre-pandemic sales in 2019, Medical Devices sales increased 18.5 percent on a reported basis and 16.1 percent on an organic basis in the third quarter, led by double-digit growth in Electrophysiology, Heart Failure, Structural Heart and Diabetes Care.⁶

In Diabetes Care, FreeStyle Libre^® and Libre Sense^™ sales were $968 million in the quarter, which represents sales growth of 41.6 percent on a reported basis and 38.8 percent on an organic basis.

During the quarter, Abbott continued to strengthen its Medical Devices portfolio with several new products, including:

·

U.S. FDA approval of Amplatzer Amulet Left Atrial Appendage Occluder to treat people with atrial fibrillation who are at risk of ischemic stroke.

·

U.S. FDA approval of Portico with FlexNav transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high risk for open-heart surgery.

·

U.S. FDA approval of Amplatzer^™ Talisman^™ PFO Occlusion System to treat people with a patent foramen ovale – a small opening between the upper chambers of the heart – who are at risk of recurrent ischemic stroke.

·

Abbott acquired Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive thrombectomy system designed to remove peripheral blood clots.

6

Abbott'S EARNINGS-PER-SHARE guidance

Abbott projects 2021 diluted earnings per share from continuing operations under GAAP of $3.55 to $3.65. Abbott forecasts specified items for the full-year 2021 of $1.45 per share primarily related to intangible amortization, restructuring and cost reduction initiatives, including expenses to align its COVID-19 testing-related business with changes during the year in current and projected testing demand, expenses associated with acquisitions and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $5.00 to $5.10 for full-year 2021.

Abbott declares 391^stconsecutive QUARTERLY DIVIDEND

On Sept. 15, 2021, the board of directors of Abbott declared the company's quarterly dividend of $0.45 per share. Abbott's cash dividend is payable Nov. 15, 2021 to shareholders of record at the close of business on Oct. 15, 2021.

Abbott has increased its dividend payout for 49 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

Abbott will live-webcast its third-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later that day.

7

— Private Securities Litigation Reform Act of 1995 —

A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2020, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Abbott Financial:

Scott Leinenweber, 224-668-0791

Michael Comilla, 224-668-1872

Laura Dauer, 224-667-2299

Abbott Media:

Katie Stafford, 224-668-2121

Kate Dyer, 224-668-9965

¹

Third-quarter 2021 diluted EPS from continuing operations on a GAAP basis reflects 69.6 percent growth.

²

Full-year 2021 guidance for diluted EPS from continuing operations on a GAAP basis reflects growth of 44.5 percent at the mid-point versus prior year.

³

In the third quarter of 2019, worldwide sales were $8.076 billion. In the third quarter of 2021, COVID-19 testing-related sales were $1.908 billion. In the nine months of 2019, worldwide sales were $23.590 billion. In the nine months of 2021, COVID-19 testing-related sales were $5.360 billion.

⁴

In the third quarter of 2020, Diagnostics sales were $2.64 billion, which included COVID-19 testing-related sales of $0.9 billion.

⁵

In the third quarter of 2019, Core Laboratory and Molecular Diagnostics sales were $1.177 billion and $111 million, respectively. In the third quarter of 2021, COVID-19 testing-related sales for Core Laboratory and Molecular Diagnostics were $47 million and $218 million, respectively.

⁶

In the third quarter of 2019, Medical Devices sales were $3.065 billion.

8

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Third Quarter Ended September 30, 2021 and 2020

(in millions, except per share data)

(unaudited)

			3Q21				3Q20				% Change
Net Sales		$	10,928			$	8,853				23.4

Cost of products sold, excluding amortization expense			4,423				3,966				11.5
Amortization of intangible assets			520				510				1.8
Research and development			672				580				16.1
Selling, general, and administrative			2,767				2,302				20.2
Total Operating Cost and Expenses			8,382				7,358				13.9

Operating Earnings			2,546				1,495				70.2

Interest expense, net			123				127				(3.3)
Net foreign exchange (gain) loss			4				(7	)			n/m
Other (income) expense, net			(74	)			(46	)			63.1
Earnings from Continuing Operations before taxes			2,493				1,421				75.3

Tax expense on Earnings from Continuing Operations			393				189				107.3	1)
Earnings from Continuing Operations			2,100				1,232				70.4

Earnings from Discontinued Operations, net of taxes			--				--				n/m

Net Earnings		$	2,100			$	1,232				70.4

Earnings from Continuing Operations, excluding
Specified Items, as described below		$	2,518			$	1,760				43.1	2)

Diluted Earnings per Common Share from:
Continuing Operations		$	1.17			$	0.69				69.6
Discontinued Operations			--				--				n/m
Total		$	1.17			$	0.69				69.6

Diluted Earnings per Common Share from Continuing
Operations, excluding Specified Items, as described below		$	1.40			$	0.98				42.9	2)

Average Number of Common Shares Outstanding
Plus Dilutive Common Stock Options			1,789				1,788

NOTES:

See tables on page 13 for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following page.

9

¹⁾

2020 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $20 million in excess tax benefits associated with share-based compensation.

²⁾

2021 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $418 million, or $0.23 per share, for intangible amortization and other expenses primarily associated with restructuring actions and acquisitions, partially offset by a change in estimate to the restructuring actions recognized in the second quarter related to Abbott's manufacturing network for COVID-19 diagnostic tests to reflect current and projected demand.

2020 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $528 million, or $0.29 per share, for intangible amortization and impairment expenses and other net expenses primarily associated with acquisitions, restructuring actions and income from a litigation settlement.

10

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Nine Months Ended September 30, 2021 and 2020

(in millions, except per share data)

(unaudited)

			9M21				9M20			% Change
Net Sales		$	31,607			$	23,907			32.2

Cost of products sold, excluding amortization expense			13,771				10,510			31.0
Amortization of intangible assets			1,533				1,624			(5.7)
Research and development			1,980				1,722			15.0
Selling, general, and administrative			8,276				7,126			16.1
Total Operating Cost and Expenses			25,560				20,982			21.8

Operating Earnings			6,047				2,925			106.7

Interest expense, net			370				373			(0.7)
Net foreign exchange (gain) loss			7				(3	)		n/m
Other (income) expense, net			(214	)			(25	)		n/m
Earnings from Continuing Operations before taxes			5,884				2,580			128.0

Tax expense on Earnings from Continuing Operations			802				267			n/m	1)
Earnings from Continuing Operations			5,082				2,313			119.7

Earnings from Discontinued Operations, net of taxes			--				20			n/m

Net Earnings		$	5,082			$	2,333			117.8

Earnings from Continuing Operations, excluding
Specified Items, as described below		$	7,001			$	3,940			77.7	2)

Diluted Earnings per Common Share from:
Continuing Operations		$	2.83			$	1.29			119.4
Discontinued Operations			--				0.01			n/m
Total		$	2.83			$	1.30			117.7

Diluted Earnings per Common Share from Continuing
Operations, excluding Specified Items, as described below		$	3.89			$	2.20			76.8	2)

Average Number of Common Shares Outstanding
Plus Dilutive Common Stock Options			1,791				1,785

NOTES:

See tables on page 14 for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following page.

11

1)	2021 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $97 million in excess tax benefits associated with share-based compensation.

2020 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $80 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $87 million in excess tax benefits associated with share-based compensation.

2)

2021 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $1.919 billion, or $1.06 per share, for intangible amortization and other net expenses primarily associated with restructuring actions, certain litigation and acquisitions.

2020 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $1.627 billion, or $0.91 per share, for intangible amortization expense, impairment charges and other net expense primarily associated with acquisitions, restructuring actions and income from a litigation settlement.

12

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information From Continuing Operations

Third Quarter Ended September 30, 2021 and 2020

(in millions, except per share data)

(unaudited)

		3Q21
		As Reported (GAAP)				Specified Items				As Adjusted				% to Sales
Intangible Amortization		$	520			$	(520	)		$	--
Gross Margin			5,985				445				6,430				58.8	%
R&D			672				(21	)			651				6.0	%
SG&A			2,767				(30	)			2,737				25.0	%
Other (income) expense, net			(74	)			7				(67	)
Earnings from Continuing Operations before taxes			2,493				489				2,982
Tax expense on Earnings from Continuing Operations			393				71				464
Earnings from Continuing Operations			2,100				418				2,518
Diluted Earnings per Share from Continuing Operations		$	1.17			$	0.23			$	1.40

Specified items reflect intangible amortization expense of $520 million and net pretax income of $31 million, primarily associated with a change in estimate to the restructuring actions recognized in the second quarter, partially offset by costs associated with acquisitions and other expenses. See page 16 for additional details regarding specified items.

		3Q20
		As Reported (GAAP)				Specified Items				As Adjusted				% to Sales
Intangible Amortization		$	510			$	(510	)		$	--
Gross Margin			4,377				705				5,082				57.4	%
R&D			580				(21	)			559				6.3	%
SG&A			2,302				63				2,365				26.7	%
Other (income) expense, net			(46	)			(1	)			(47	)
Earnings from Continuing Operations before taxes			1,421				664				2,085
Tax expense on Earnings from Continuing Operations			189				136				325
Earnings from Continuing Operations			1,232				528				1,760
Diluted Earnings per Share from Continuing Operations		$	0.69			$	0.29			$	0.98

Specified items reflect intangible amortization expense of $510 million and other net expenses of $154 million, primarily associated with acquisitions, restructuring actions and other expenses and litigation settlement income. See page 17 for additional details regarding specified items.

13

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information From Continuing Operations

Nine Months Ended September 30, 2021 and 2020

(in millions, except per share data)

(unaudited)

			9M21
			As Reported (GAAP)				Specified Items				As Adjusted				% to Sales
Intangible Amortization		$	1,533			$	(1,533	)		$	--
Gross Margin			16,303				2,042				18,345				58.0	%
R&D			1,980				(67	)			1,913				6.1	%
SG&A			8,276				(274	)			8,002				25.3	%
Other (income) expense, net			(214	)			30				(184	)
Earnings from Continuing Operations before taxes			5,884				2,353				8,237
Tax expense on Earnings from Continuing Operations			802				434				1,236
Earnings from Continuing Operations			5,082				1,919				7,001
Diluted Earnings per Share from Continuing Operations		$	2.83			$	1.06			$	3.89

Specified items reflect intangible amortization expense of $1.533 billion and other net expenses of $820 million, primarily associated with restructuring actions, certain litigation, acquisitions and other expenses. See page 18 for additional details regarding specified items.

			9M20
			As Reported (GAAP)				Specified Items				As Adjusted				% to Sales
Intangible Amortization		$	1,624			$	(1,624	)		$	--
Gross Margin			11,773				1,895				13,668				57.2	%
R&D			1,722				(64	)			1,658				6.9	%
SG&A			7,126				(19	)			7,107				29.7	%
Other (income) expense, net			(25	)			(111	)			(136	)
Earnings from Continuing Operations before taxes			2,580				2,089				4,669
Tax expense on Earnings from Continuing Operations			267				462				729
Earnings from Continuing Operations			2,313				1,627				3,940
Diluted Earnings per Share from Continuing Operations		$	1.29			$	0.91			$	2.20

Specified items reflect intangible amortization expense of $1.624 billion and other net expenses of $465 million, primarily associated with acquisitions, restructuring actions and other expenses and litigation settlement income. See page 19 for additional details regarding specified items.

14

A reconciliation of the third-quarter tax rates for continuing operations for 2021 and 2020 is shown below:

			3Q21
($ in millions)			Pre-Tax Income				Taxes on Earnings				Tax Rate
As reported (GAAP)		$	2,493			$	393				15.7	%
Specified items			489				71
Excluding specified items		$	2,982			$	464				15.5	%

			3Q20
($ in millions)			Pre-Tax Income				Taxes on Earnings				Tax Rate
As reported (GAAP)		$	1,421			$	189				13.3	%			1	)
Specified items			664				136
Excluding specified items		$	2,085			$	325				15.6	%

1)

2020 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $20 million in excess tax benefits associated with share-based compensation.

A reconciliation of the year-to-date tax rates for continuing operations for 2021 and 2020 is shown below:

			9M21
($ in millions)			Pre-Tax Income				Taxes on Earnings				Tax Rate
As reported (GAAP)		$	5,884			$	802				13.6	%			2	)
Specified items			2,353				434
Excluding specified items		$	8,237			$	1,236				15.0	%

			9M20
($ in millions)			Pre-Tax Income				Taxes on Earnings				Tax Rate
As reported (GAAP)		$	2,580			$	267				10.4	%			3	)
Specified items			2,089				462
Excluding specified items		$	4,669			$	729				15.6	%

2)

2021 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $97 million in excess tax benefits associated with share-based compensation.

3)

2020 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $80 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $87 million in excess tax benefits associated with share-based compensation.

15

Abbott Laboratories and Subsidiaries

Details of Specified Items

Third Quarter Ended September 30, 2021

(in millions, except per share data)

(unaudited)

		Acquisition or Divestiture- related (a)				Restructuring and Cost Reduction Initiatives (b)				Intangible Amortization				Other (c)				Total Specifieds
Gross Margin		$	16			$	(96	)		$	520			$	5			$	445
R&D			(4	)			--				--				(17	)			(21	)
SG&A			(12	)			(23	)			--				5				(30	)
Other (income) expense, net			6				--				--				1				7
Earnings from Continuing Operations before taxes		$	26			$	(73	)		$	520			$	16				489
Tax expense on Earnings from Continuing Operations (d)																			71
Earnings from Continuing Operations																		$	418
Diluted Earnings per Share from Continuing Operations																		$	0.23

The table above provides additional details regarding the specified items described on page 13.

a)

Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites. The Gross Margin amount includes a credit associated with a change in estimate to the charges taken in the second quarter for a restructuring plan related to Abbott's manufacturing network for COVID-19 diagnostic tests to reflect current and projected demand.

c)

Other includes incremental costs to comply with the European Union's Medical Device (MDR) and In Vitro Diagnostics Medical Device (IVDR) Regulations for previously approved products.

d)

Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.

16

Abbott Laboratories and Subsidiaries

Details of Specified Items

Third Quarter Ended September 30, 2020

(in millions, except per share data)

(unaudited)

		Acquisition or Divestiture- related (a)				Restructuring and Cost Reduction Initiatives (b)				Intangible Amortization				Other (c)				Total Specifieds
Gross Margin		$	16			$	27			$	510			$	152			$	705
R&D			(1	)			(1	)			--				(19	)			(21	)
SG&A			(28	)			(9	)			--				100				63
Other (income) expense, net			(2	)			--				--				1				(1	)
Earnings from Continuing Operations before taxes		$	47			$	37			$	510			$	70				664
Tax expense on Earnings from Continuing Operations (d)																			136
Earnings from Continuing Operations																		$	528
Diluted Earnings per Share from Continuing Operations																		$	0.29

The table above provides additional details regarding the specified items described on page 13.

a)	Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for retention and the integration of systems, processes and business activities.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites.

c)	Other primarily relates to the impairment of an intangible asset and the costs to acquire R&D assets, partially offset by income from the settlement of litigation.

d)	Reflects the net tax benefit associated with the specified items, the resolution of prior years' tax positions and excess tax benefits associated with share-based compensation.

17

Abbott Laboratories and Subsidiaries

Details of Specified Items

Nine Months Ended September 30, 2021

(in millions, except per share data)

(unaudited)

		Acquisition or Divestiture- related (a)				Restructuring and Cost Reduction Initiatives (b)				Intangible Amortization				Other (c)				Total Specifieds
Gross Margin		$	56			$	433			$	1,533			$	20			$	2,042
R&D			(9	)			1				--				(59	)			(67	)
SG&A			(43	)			(22	)			--				(209	)			(274	)
Other (income) expense, net			3				1				--				26				30
Earnings from Continuing Operations before taxes		$	105			$	453			$	1,533			$	262				2,353
Tax expense on Earnings from Continuing Operations (d)																			434
Earnings from Continuing Operations																		$	1,919
Diluted Earnings per Share from Continuing Operations																		$	1.06

The table above provides additional details regarding the specified items described on page 14.

a)	Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites. The Gross Margin amount includes charges associated with a restructuring plan to align Abbott's manufacturing network for COVID-19 diagnostic tests with changes during the year in current and projected testing demand.

c)	Other primarily relates to the costs related to certain litigation, the acquisition of a research and development asset, the impairments of an equity investment and an intangible asset, and the gain on the disposition of an equity method investment.

d)	Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.

18

Abbott Laboratories and Subsidiaries

Details of Specified Items

Nine Months Ended September 30, 2020

(in millions, except per share data)

(unaudited)

		Acquisition or Divestiture- related (a)				Restructuring and Cost Reduction Initiatives (b)				Intangible Amortization				Other (c)				Total Specifieds
Gross Margin		$	61			$	57			$	1,624			$	153			$	1,895
R&D			(8	)			(9	)			--				(47	)			(64	)
SG&A			(83	)			(36	)			--				100				(19	)
Other (income) expense, net			(3	)			--				--				(108	)			(111	)
Earnings from Continuing Operations before taxes		$	155			$	102			$	1,624			$	208				2,089
Tax expense on Earnings from Continuing Operations (d)																			462
Earnings from Continuing Operations																		$	1,627
Diluted Earnings per Share from Continuing Operations																		$	0.91

The table above provides additional details regarding the specified items described on page 14.

a)	Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for retention, severance, and the integration of systems, processes and business activities.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites.

c)	Other primarily relates to impairment charges related to certain assets and the costs to acquire R&D assets, partially offset by income from the settlement of litigation.

d)	Reflects the net tax benefit associated with the specified items, the resolution of prior years' tax positions and excess tax benefits associated with share-based compensation.

# # #

19

EX-101.SCH 3 abt-20211020.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 abt-20211020_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 abt-20211020_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Common Stock [Member] Entity Listings, Exchange [Axis] CHICAGO STOCK EXCHANGE, INC [Member] NEW YORK STOCK EXCHANGE, INC. [Member] Entity Listings [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 abt-20211020_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm2130546d1_ex99-1image1.jpg GRAPHIC begin 644 tm2130546d1_ex99-1image1.jpg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end XML 8 tm2130546d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000001800 2021-10-20 2021-10-20 0000001800 us-gaap:CommonStockMember exch:XCHI 2021-10-20 2021-10-20 0000001800 us-gaap:CommonStockMember exch:XNYS 2021-10-20 2021-10-20 iso4217:USD shares iso4217:USD shares 0000001800 false Common Shares, Without Par Value ABT 8-K 2021-10-20 ABBOTT LABORATORIES IL 1-2189 36-0698440 100 Abbott Park Road Abbott Park IL 60064-6400 224 667-6100 false false false false Common Shares, Without Par Value ABT NYSE CHX false XML 9 R1.htm IDEA: XBRL DOCUMENT

Cover	Oct. 20, 2021
Document Information [Line Items]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Oct. 20, 2021
Entity File Number	1-2189
Entity Registrant Name	ABBOTT LABORATORIES
Entity Central Index Key	0000001800
Entity Tax Identification Number	36-0698440
Entity Incorporation, State or Country Code	IL
Entity Address, Address Line One	100 Abbott Park Road
Entity Address, City or Town	Abbott Park
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60064-6400
City Area Code	224
Local Phone Number	667-6100
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Common Stock [Member] \| CHICAGO STOCK EXCHANGE, INC [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Shares, Without Par Value
Trading Symbol	ABT
Security Exchange Name	CHX
Common Stock [Member] \| NEW YORK STOCK EXCHANGE, INC. [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Shares, Without Par Value
Trading Symbol	ABT
Security Exchange Name	NYSE

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 3 96 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://abbott.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2130546d1_8k.htm abt-20211020.xsd abt-20211020_def.xml abt-20211020_lab.xml abt-20211020_pre.xml tm2130546d1_ex99-1.htm http://xbrl.sec.gov/exch/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2130546d1_8k.htm": { "axisCustom": 0, "axisStandard": 2, "contextCount": 3, "dts": { "definitionLink": { "local": [ "abt-20211020_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2130546d1_8k.htm" ] }, "labelLink": { "local": [ "abt-20211020_lab.xml" ] }, "presentationLink": { "local": [ "abt-20211020_pre.xml" ] }, "schema": { "local": [ "abt-20211020.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 68, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 3, "nsprefix": "abt", "nsuri": "http://abbott.com/20211020", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2130546d1_8k.htm", "contextRef": "From2021-10-20to2021-10-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://abbott.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2130546d1_8k.htm", "contextRef": "From2021-10-20to2021-10-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingsExchangeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Listings, Exchange [Axis]" } } }, "localname": "EntityListingsExchangeAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_ExchangeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "localname": "ExchangeDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "exch_XCHI": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHICAGO STOCK EXCHANGE, INC [Member]" } } }, "localname": "XCHI", "nsuri": "http://xbrl.sec.gov/exch/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "exch_XNYS": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW YORK STOCK EXCHANGE, INC. [Member]" } } }, "localname": "XNYS", "nsuri": "http://xbrl.sec.gov/exch/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 17 0001104659-21-127874-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-127874-xbrl.zip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end